Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
September 09, 2024 08:05 ET
|
Protara Therapeutics
TARA-002 demonstrated compelling efficacy and was generally well-tolerated Enrollment in additional cohorts underway with initial results expected in 1H’25 NEW YORK, Sept. 09, 2024 (GLOBE...
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
September 09, 2024 08:00 ET
|
Protara Therapeutics
78% of patients dependent on parenteral support were choline deficient, with 63% of these patients demonstrating liver dysfunction, including steatosis, cholestasis, and hepatobiliary injuryIV Choline...
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 08:00 ET
|
Protara Therapeutics
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
August 06, 2024 08:00 ET
|
Protara Therapeutics
On track to report preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in Q4 2024 Expect to dose first patient in pivotal trial for IV Choline Chloride in Q1...
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 24, 2024 17:06 ET
|
Protara Therapeutics
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
May 21, 2024 08:00 ET
|
Protara Therapeutics
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
May 02, 2024 08:00 ET
|
Protara Therapeutics
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBCPreliminary data from six-month evaluable patients in ADVANCED-2 trial of...
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
April 05, 2024 08:04 ET
|
Protara Therapeutics
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
April 05, 2024 08:02 ET
|
Protara Therapeutics
New development pathway significantly expands addressable patient population for IV Choline ChlorideIV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for...
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
April 05, 2024 08:00 ET
|
Protara Therapeutics
TARA-002 demonstrated a complete response rate of 43% at three months in BCG-Unresponsive/Experienced patients in ongoing NMIBC programTARA-002 demonstrated a complete response rate of 63% at three...